{"prompt": "['- Stool sample: stool samples will be used for 16S rRNA detection of microbiota bacteria and will be sent to the', 'Laboratory for microbiota analysis, Gut Microbiota and Immunity lab (Pr Harry Sokol), INSERM U1157 / UMR', 'CNRS 7203, Universit\u00e9 Pierre et Marie Curie, 27 rue de Chaligny, 75012 Paris, France.', 'Conduct of analyses :', '1/ Blood samples:', '- Measurement of ctDNA:', '*', 'total concentration of circulating DNA', 'ctDNA concentration (Garrigou et al. Clin Chem 2016, Pecuchet Clin Chem 2016)', '2/ A block of tumour tissue embedded in paraffin:', '- Extraction of DNA for:', '* microsatellite instability', '*', 'gastric molecular subgroup', '*', 'tumour mutation load', '- Construction of the Tissue Micro Array block for immunohistochemistry:', '* expression of immune checkpoints (PD-L1, PD-L2)', '*', 'immune response/immune scores', '3/ Stool samples:', '- Extraction of 16S rRNA:', '* identification of bacteria composing the intestinal microbiota of patients', 'Bibliography:', '1. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev', 'Cancer. 2011;11:426-37', '2. Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA', 'apoptosis and active DNA release. Clin Chim Acta. 2001;313:139-42', '3. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-', 'EGFR therapy in colorectal cancer. Nature. 2012;486:532-6', '4. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR', 'blockade in colorectal cancers. Nature. 2012;486:537-40.', '5. Granier C, Roussel H, de Guillebon E, et al. Biomarkers from the tumor microenvironment to predict', 'clinical response to checkpoint inhibitors. J OncoPathology 2014.', '6.', 'Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science', '2013;339:1546-58.', '7. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects', 'of cyclophosphamide. Science 2013;342:971-6.', '8. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1', 'immunotherapy in melanoma patients. Science 2018;359:97-103.', '9. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based', 'immunotherapy against epithelial tumors. Science 2018;359:91-97.', '10.', 'Carbonnel F, Soularue E, Coutzac C, et al. Inflammatory bowel disease and cancer response due to anti-', 'CTLA-4: is it in the flora? Semin Immunopathol 2017;39:327-31.', '11. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic', 'sequencing. Nature 2010;464:59-65.', '12. Lamas B, Richard ML, Leducq V, et al. CARD9 impacts colitis by altering gut microbiota metabolism', 'of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 2016;22:598-605.', '13. Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66:1039-1048', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 79 de 123']['APPENDIX 3: QUALITY OF LIFE - QLQ-C30', 'EORTC QLQ-C30 (version 3.0) - PRODIGE 59 - DURIGAST', 'We are interested in some things about you and your health. Please answer all of the questions yourself by circling the', 'number that best applies to you. There are no \"right\" or \"wrong\" answers. The information that you provide will remain', 'strictly confidential.', 'Please fill in:', 'The first three letters of your surname:', 'The first two letters of your first name:', 'Your date of birth:', \"Today's date:\", 'Not at all', 'A little', 'Quite a', 'Very much', 'bit', '1. Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or', '1', '2', '3', '4', 'suitcase?', '2. Do you have any trouble taking a long walk?', '1', '2', '3', '4', '3. Do you have any trouble taking a short walk outside the house?', '1', '2', '3', '4', '4. Do you need to stay in bed or in a chair during the day?', '1', '2', '3', '4', '5 Do you need help with eating, dressing, washing yourself or using the toilet?', '1', '2', '3', '4', 'During the past week:', 'Quite a', 'Not at all', 'A little', 'bit', 'Very much', '6. Were you limited in doing either your work or other daily activities?', '1', '2', '3', '4', '7. Were you limited in pursuing your hobbies or other leisure time activities?', '1', '2', '3', '4', '8. Were you short of breath?', '1', '2', '3', '4', '9. Have you had pain?', '1', '2', '3', '4', '10. Did you need to rest?', '1', '2', '3', '4', '11. Have you had trouble sleeping?', '1', '2', '3', '4', '12. Have you felt weak?', '1', '2', '3', '4', '13. Have you lacked appetite?', '1', '2', '3', '4', '14. Have you felt nauseated?', '1', '2', '3', '4', '15. Have you vomited?', '1', '2', '3', '4', '16. Have you been constipated?', '1', '2', '3', '4', '17. Have you had diarrhea?', '1', '2', '3', '4', '18. Were you tired?', '1', '2', '3', '4', '19. Did pain interfere with your daily activities?', '1', '2', '3', '4', '20. Have you had difficulty in concentrating on things, like reading a newspaper or watching', '1', '2', '3', '4', 'television?', '21. Did you feel tense?', '1', '2', '3', '4', '22. Did you worry?', '1', '2', '3', '4', '23. Did you feel irritable?', '1', '2', '3', '4', '24. Did you feel depressed?', '1', '2', '3', '4', '25. Have you had difficulty remembering things?', '1', '2', '3', '4', '26. Has your physical condition or medical treatment interfered with the family life?', '1', '2', '3', '4', '27. Has your physical condition or medical treatment interfered with your social activities?', '1', '2', '3', '4', '28. Has your physical condition or medical treatment caused you financial difficulties?', '1', '2', '3', '4', 'For the following questions, please circle the number between 1 and 7 that best applies to you', '29. How would you rate your overall health during the last week?', '1', '2', '3', '4', '5', '6', '7', 'Very poor', 'Excellent', '30. How would you rate your overall quality of life during the last week?', '1', '2', '3', '4', '5', '6', '7', 'Very poor', 'Excellent', 'C Copyright 1999 EORTC Quality of Life Study Group, version 3.0. All rights reserved. English version', 'The data collected will be analyzed by computer. In accordance with the law \"Informatique et Libert\u00e9\" of January 6, 1978 amended by law 2004-801 of August 6, 2004 relating', 'to the automated processing of health data, you may exercise a right of access and modification through your investigator.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 80 de 123']\n\n###\n\n", "completion": "END"}